CN103554017B - 一种孟鲁司特钠手性中间体的制备方法 - Google Patents
一种孟鲁司特钠手性中间体的制备方法 Download PDFInfo
- Publication number
- CN103554017B CN103554017B CN201310510321.1A CN201310510321A CN103554017B CN 103554017 B CN103554017 B CN 103554017B CN 201310510321 A CN201310510321 A CN 201310510321A CN 103554017 B CN103554017 B CN 103554017B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- reaction
- montelukast
- chiral intermediate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title claims abstract description 14
- 229960005127 montelukast Drugs 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 77
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 9
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 claims abstract description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 claims abstract description 8
- 238000007259 addition reaction Methods 0.000 claims abstract description 3
- 230000001590 oxidative effect Effects 0.000 claims abstract description 3
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- PSEHHVRCDVOTID-VMAIWCPRSA-N chloro-bis[(1r,3r,4s,5r)-4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl]borane Chemical compound C([C@H]([C@@H]1C)B(Cl)[C@H]2[C@H](C)[C@]3(C[C@@](C2)(C3(C)C)[H])[H])[C@@]2([H])C(C)(C)[C@]1([H])C2 PSEHHVRCDVOTID-VMAIWCPRSA-N 0.000 claims description 6
- UOALEFQKAOQICC-UHFFFAOYSA-N chloroborane Chemical compound ClB UOALEFQKAOQICC-UHFFFAOYSA-N 0.000 claims description 6
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 claims description 6
- 229910001623 magnesium bromide Inorganic materials 0.000 claims description 6
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims description 3
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims description 3
- 229940045803 cuprous chloride Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000005660 chlorination reaction Methods 0.000 claims description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 6
- 239000000047 product Substances 0.000 abstract description 5
- 238000006555 catalytic reaction Methods 0.000 abstract description 4
- 230000003287 optical effect Effects 0.000 abstract description 3
- 239000010970 precious metal Substances 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 abstract 2
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 description 3
- 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- RLICUPZTDXYULB-UHFFFAOYSA-N [Na].C1(CC1)CC(=O)O Chemical compound [Na].C1(CC1)CC(=O)O RLICUPZTDXYULB-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- -1 chloro-2-quinolyl Chemical group 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001951 montelukast sodium Drugs 0.000 description 1
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000012485 toluene extract Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310510321.1A CN103554017B (zh) | 2013-10-25 | 2013-10-25 | 一种孟鲁司特钠手性中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310510321.1A CN103554017B (zh) | 2013-10-25 | 2013-10-25 | 一种孟鲁司特钠手性中间体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103554017A CN103554017A (zh) | 2014-02-05 |
CN103554017B true CN103554017B (zh) | 2014-12-17 |
Family
ID=50008423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310510321.1A Active CN103554017B (zh) | 2013-10-25 | 2013-10-25 | 一种孟鲁司特钠手性中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103554017B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0480717A1 (en) * | 1990-10-12 | 1992-04-15 | Merck Frosst Canada Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
CN101638381A (zh) * | 2009-09-02 | 2010-02-03 | 鲁南制药集团股份有限公司 | 孟鲁司特钠中间体的合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2094665A4 (en) * | 2006-11-06 | 2010-11-24 | Reddys Lab Ltd Dr | PREPARATION OF MONTELUKAST AND ITS SALTS |
-
2013
- 2013-10-25 CN CN201310510321.1A patent/CN103554017B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0480717A1 (en) * | 1990-10-12 | 1992-04-15 | Merck Frosst Canada Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
CN101638381A (zh) * | 2009-09-02 | 2010-02-03 | 鲁南制药集团股份有限公司 | 孟鲁司特钠中间体的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103554017A (zh) | 2014-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101679353A (zh) | 制备化合物2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈701的新方法 | |
CN108033922B (zh) | 一种3-酰基喹喔啉酮衍生物的制备方法 | |
CN102633686A (zh) | 一种帕拉米韦的制备方法 | |
CN103936671A (zh) | 孟鲁司特钠中间体的制备方法 | |
CN106916111A (zh) | 一种(s)-2-甲基-1,4,5,6-四氢甲基嘧啶-4-羧酸的合成方法 | |
CN103864813B (zh) | 一种合成六氢呋喃并[2,3‑b]呋喃‑3‑醇及其对映体的方法 | |
CN104086545A (zh) | 1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-甲脒盐酸盐的合成方法 | |
CN104311485B (zh) | 一种治疗白血病的药物博舒替尼的制备方法 | |
CN103554017B (zh) | 一种孟鲁司特钠手性中间体的制备方法 | |
CN108395440A (zh) | 一种利用没食子酸衍生物合成鞣花酸的方法 | |
CN109232184B (zh) | 一种通过手性拆分提高l-异胡薄荷醇光学纯度的方法 | |
CN107353245B (zh) | 一种喹啉类化合物的合成方法 | |
CN110128385A (zh) | 一种通过十二酰氯化学修饰的槲皮素衍生物及其合成方法 | |
CN105348241A (zh) | 一种硫酸沃拉帕沙中间体的合成方法 | |
CN106749098B (zh) | 一种以氧气为氧化剂制备盐酸二氧丙嗪的制备方法 | |
CN104610037A (zh) | β-三氟甲基-β-羟基酮的制备方法 | |
CN104230790B (zh) | 一种西他沙星侧链中间体制备方法 | |
CN103664941B (zh) | 一种长春西汀类似物的制备方法 | |
CN102079720B (zh) | 一种制备1-苄基-4-哌啶甲醛的方法 | |
CN106748884A (zh) | 一种比卡鲁胺中间体的制备方法 | |
CN103214424B (zh) | 吡嗪甲胺衍生物的合成方法 | |
CN113387791B (zh) | 一种盐酸伊伐布雷定关键中间体的合成方法 | |
CN103319432B (zh) | 一种合成伊拉地平药物中间体4-甲酰基苯并呋咱的方法 | |
CN105237592A (zh) | 一种阿洛糖衍生物的制备方法 | |
CN113512086B (zh) | 一种制备螺内酯中间体坎利酮的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of montelukast chiral intermediate Effective date of registration: 20170418 Granted publication date: 20141217 Pledgee: Bank of Cangzhou Limited by Share Ltd. branch Pledgor: HEBEI XUNENG BIOTECHNOLOGY CO.,LTD. Registration number: 2017990000323 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190416 Granted publication date: 20141217 Pledgee: Bank of Cangzhou Limited by Share Ltd. branch Pledgor: HEBEI XUNENG BIOTECHNOLOGY CO.,LTD. Registration number: 2017990000323 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190515 Address after: 061000 North of Wei2 Road and West of Jingwu Road in Bohai New Area, Cangzhou City, Hebei Province Patentee after: CANGZHOU SENARY CHEMICAL SCIENCE-TEC CO.,LTD. Address before: 061000 Economic and Technological Development of Lingang City, Cangzhou City, Hebei Province Patentee before: HEBEI XUNENG BIOTECHNOLOGY CO.,LTD. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of a chiral intermediate of montelukast sodium Effective date of registration: 20210420 Granted publication date: 20141217 Pledgee: Bank of Cangzhou Limited by Share Ltd. branch Pledgor: CANGZHOU SENARY CHEMICAL SCIENCE-TEC Co.,Ltd. Registration number: Y2021990000345 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230418 Granted publication date: 20141217 Pledgee: Bank of Cangzhou Limited by Share Ltd. branch Pledgor: CANGZHOU SENARY CHEMICAL SCIENCE-TEC CO.,LTD. Registration number: Y2021990000345 |